finance.yahoo.comOct 30$MMSI

Merit Medical Systems Inc (MMSI) (Q3 2026) Earnings Call Highlights: Revenue Tops $416

Merit Medical Systems (MMSI) reported Q3 2026 revenue of $416M, with 9% organic growth. Gross margin declined to 52.8% due to manufacturing and freight costs. China market challenges reduced the second-half outlook by $4M. Inventory increased by $60M due to strategic stockpiling. CEO Martha Aronson expressed confidence in growth but declined to comment on 2027. The company is targeting OneMark at new accounts and expects $600M in free cash flow.

Original reporting

finance.yahoo.com

Published Oct 30, 2026, 7:12 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Oct 30, 2026, 7:16 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Source · finance.yahoo.com

Decision brief

The 30-second read

$MMSIBullishHigh

Why it matters

Revenue beat, guidance raised, but margin and inventory issues noted.

Market read

Merit’s earnings beat and upgraded guidance provide a clear short-term trading catalyst.

What to watch

China regulatory risks and pending tariff refunds may affect future performance

Relevance 8/10Novelty 9/10Timing: pre-market today

Background

Merit Medical Systems reported Q3 2026 results, revenue $416M, raised guidance, noted margin decline, inventory increase, and China outlook reduction.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$MMSIBullishHigh confidence

Context

Q3 2026 earnings call revealed $416M revenue, raised low end of guidance and EPS, lifted operating margin.

Expected impact

modest upside as guidance lift may outweigh margin pressure

Evidence & confidence

Guidance improvement suggests earnings beat, yet margin and inventory concerns temper enthusiasm.

Market effects

Sector

Medical device sector may benefit from Merit’s raised outlook

Regional

U.S. healthcare stocks could see slight uplift

Global

Primarily relevant to U.S. investors

Counterpoint

What could challenge this read

Margin compression and high inventory could pressure the stock

Key entities

company
Merit Medical Systems
Medical device maker reporting Q3 2026 earnings
executive
Martha Aronson
CEO of Merit Medical Systems, provided commentary on earnings
executive
Raul Parra
CFO of Merit Medical Systems, discussed financial details

Read at source ← All news

$MMSIMedAI 8/10

Merit Medical Systems, Inc. (MMSI) Reports 92.7% Six-Month TLPP in AVF Cohort

Merit Medical reported 6-month data from 237 AVF patients in 9 countries, showing 92.7% TLPP and 76.7% ACPP, compared to prior trial rates of 89.8% and 72.8%. The company aims to expand evidence with longer follow-up and additional registries.

tradingview.comNov 5

$MMSIMedAI 8/10

At six months, 92.7% of patients needed no repeat procedure for the treated dialysis-access blockage.

Merit Medical Systems (MMSI) reported 6-month data from the WRAP Global registry, showing 92.7% target lesion primary patency and 76.7% access circuit primary patency for its WRAPSODY CIE device in arteriovenous fistula patients. Results exceeded those from prior trials, according to the company. The device is FDA-approved and commercially available in the U.S., EU, and other regions.

stocktitan.netNov 5

$MMSIHighAI 8/10

MMSI Q3 deep dive: balanced organic growth, new acquisitions, and margin improvement

MMSI reported Q3 revenue of $416.2M, beating estimates by 1.5%, and raised full-year guidance to $1.64B. Adjusted EPS was $1.12, a 7.8% beat, with guidance increased to $4.35. Operating margin improved to 14.1% from 11.1%. Growth was driven by foundational and therapeutic segments, with strong demand in oncology and endoscopy. The company acquired Solo Pace to expand its Cardiac Therapies platform.

finance.yahoo.comNov 1

$MMSIHigh

Merit Acquires Solo Pace For $45 Mln; Shares Down

Merit Medical Systems (MMSI) acquired Solo Pace, Inc. for $45 million, adding its pacing systems to Merit's Cardiac Therapies. The deal expands Merit's structural heart portfolio. Shares fell 6.84% to $87.00.

rttnews.comOct 30

$MMSIMed

Canaccord raises Merit Medical stock price target on Q3 beat

Canaccord raised its price target on Merit Medical Systems (MMSI) to $121 from $94, maintaining a Buy rating. The company reported Q3 revenue of $416.2M, up 8% YoY, and EPS of $1.12, up 22% YoY, both beating estimates. MMSI raised its fiscal 2026 EPS guidance to $4.33-$4.37. The stock is up 37% over six months and near its 52-week high.

investing.comOct 30